MBS 314
Alternative Names: MBS-314Latest Information Update: 27 Mar 2024
At a glance
- Originator Beijing Mabworks Biotech
- Class Antineoplastics; Immunotherapies; Trispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Multiple myeloma
Most Recent Events
- 22 Feb 2024 Phase-I/II clinical trials in Multiple myeloma (Second-line therapy or greater) in China (IV) (NCT06232096)
- 14 Apr 2023 Preclinical trials in Multiple myeloma in China (Parenteral)
- 14 Apr 2023 Pharmacodynamics and adverse events data from a preclinical study in Multiple myeloma presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)